Composition:
Linapaz E 5/25
Each film-coated tablet contains
Linagliptin 5 mg + Empagliflozin 25 mg
Description:
Linagliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances incretin levels, increasing insulin release and decreasing hepatic glucose production.
Empagliflozin: A sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting urinary glucose excretion.
Together, they target complementary pathways to improve glycemic control more effectively than monotherapy.
Clinical Use:
Indicated for adults with type 2 diabetes mellitus to improve glycemic control.
Dosage & Administration: 1 tablet daily or as directed by the physician.
Contraindications:
Severe renal impairment, end-stage renal disease (ESRD), or dialysis. This product is contraindicated in patients with a known hypersensitivity to any of the ingredients.
Disclaimer:
All content published online is intended for informational purposes only and should not be considered a substitute for professional medical advice. Always consult your doctor with any questions regarding your health, medical condition, or medications.